ApoA-I mutations, L202P and K131del, in HDL from heterozygotes with low HDL-C

Proteomics - Clinical Applications

Volumn 8, Issue 3-4, 2014, Pages 241-250

  Ljunggren, Stefan ^a   Levels, Johannes H M ^b   Turkina, Maria V ^a   Sundberg, Sofie ^a   Bochem, Andrea E ^b   Hovingh, Kees ^b   Holleboom, Adriaan G ^b   Lindahl, Mats ^a   Kuivenhoven, Jan Albert ^c   Karlsson, Helen ^a,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Department of Occupational and Environmental Medicine Heart Medical Centre   (Sweden)

Author keywords

2DE; Apolipoprotein A I; High density lipoprotein

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN; PREALBUMIN; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SEMINAL PLASMA PROTEIN; SERPINA1 PROTEIN, HUMAN; ZN-ALPHA-2-GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; HETEROZYGOTE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN DETERMINATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULTRACENTRIFUGATION; BLOOD; CARDIOVASCULAR DISEASE; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE;

ALPHA 1-ANTITRYPSIN; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HETEROZYGOTE; HUMANS; MUTATION; PHENOTYPE; PREALBUMIN; SEMINAL PLASMA PROTEINS;

EID: 84898542987     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300014     Document Type: Article

References (42)

1. Lozano, R., Naghavi, M., Foreman, K., Lim, S. et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 to 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2095-2128.
2. Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., Perry, P. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302, 1993-2000.
3. Barter, P., HDL-C: role as a risk modifier. Atheroscler. Supp. 2011, 12, 267-270.
4. Davidson, M., Toth, P., High-density lipoprotein metabolism: potential therapeutic targets. Am. J. Cardiol. 2007, 100, 32N-40N
5. Besler, C., Lusher, T. F., Landmesser, U., Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol. Med. 2012, 4, 251-268.
6. Xu, S., Laccotripe, M., Huang, X., Rigotti, A. et al., Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J. Lipid Res. 1997, 3, 1289-1298.
7. Liu, T., Krieger, M., Kan, H., Zannis, V., The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type 1 (SR-B1)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-B1 is required for efficient lipid transport. J. Biol. Chem. 2002, 277, 21576-21584.
8. Sorci-Thomas, M., Thomas, M., The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc. Med. 2002, 12, 121-128.
9. Thomas, M., Bhat, S., Sorci-Thomas, M., Three-dimensional models of HDL ApoA-I: implications for its assembly and function. J. Lipid Res. 2008, 49, 1875-1883.
10. Roosbeek, S., Vanloo, B., Duverger, N., Caster, H. et al., Three arginine residues in apolipoprotein A-I are critical for activation of lecithin:cholesterol acyltransferase. J. Lipid Res. 2001, 42, 31-40.
11. Wu, Z., Wagner, M., Zheng, L., Parks, J. et al., The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 2007, 14, 861-868.
12. Hovingh, G., Brownlie, A., Bisoendial, R., Dube, M. et al., A novel ApoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J. Am. Coll. Cardiol. 2004, 44, 1429-1435.
13. Rall, S., Weisgraber, K., Mahley, R., Ogawa, Y. et al., Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. J. Biol. Chem. 1984, 259, 10063-10070.
14. Helsinki (Lys107→0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 1294-1306.
15. Amarzguioui, M., Mucchiano, G., Häggqvist, B., Westermark, P. et al., Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem. Biophys. Res. Commun. 1998, 242, 534-539.
16. Karlsson, H., Leandersson, P., Tagesson, C., Lindahl, M., Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5, 1431-1445.
17. Görg, A., Obermaier, C., Boguth, G., Harder, A. et al., The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000, 21, 1037-1053.
18. Holleboom, A., Jakulj, L., Franssen, R., Decaris, J. et al., In vivo cholesterol efflux is reduced in carriers of a mutation in APOA1. J. Lipid Res. 2013, 54, 1964-1971.
19. Daniil, G., Phedonos, A., Holleboom, A.G, Motazacker, M. et al., Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders. Clin. Chim. Acta 2011, 412, 1213-1220.
20. Borhani, D., Rogers, D., Engler, J., Brouilette, C., Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc. Natl. Acad. Sci. USA 1997, 94, 12291-12296.
21. Reschly, E., Sorci-Thomas, M., Davidson, S., Meredith, S. et al., Apolipoprotein A-I α-helices 7 and 8 modulate high-density lipoprotein subclass distribution. J. Biol. Chem. 2002, 277, 9645-9654.
22. Cech, N., Enke, C., Practical implications of some recent studies in electrospray ionization fundamentals. Mass. Spectrom. Rev. 2001, 20, 362-387.
23. Fin. J. Lipid Res. 2007, 48, 226-234.
24. Sorci-Thomas, M., Zabalawi, M., Bharadwaj, M., Wilhelm, A. et al., Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice. Biochim. Biophys. Acta 2012, 1821, 502-512
25. Nier, V., Schultz, I., Brenner, B., Forssmann, W., Raida, M., Variability in the ratio of mutant to wild-type myosin heavy chain present in the soleus muscle of patients with familial hypertrophic cardiomyopathy. A new approach for the quantication of mutant to wild-type protein. FEBS Lett. 1999, 461, 246-252.
26. Kypreos, K., Zannis, V., Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem. J. 2007, 403, 359-367.
27. Hassan, M., Waheed, A., Yadav, S., Singh, TP., Ahmad, F., Zinc α2-glycoprotein: a multidisciplinary protein. Mol. Cancer Res. 2008, 6, 892-906.
28. Yeung, D., Lam, K., Wang, Y., Tso, A., Xu, A., Serum zinc-2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in chinese subjects. J. Clin. Endocrinol. Metab. 2009, 94, 2531-2536.
29. Vaisar, T., Pennathur, S., Green, P., Gharib, S. et al., Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J. Clin. Invest. 2007, 117, 746-756.
30. Janciauskiene, S., Bais, R., Koczulla, R., Vogelmeier, C. et al., The discovery of α1-antitrypsin and its role in health and disease. Respir. Med. 2011, 105, 1129-1139.
31. Talmud, P., Martin, S., Steiner, G., Flavell, D. et al., Progression of atherosclerosis is associated with variation in the a1-antitrypsin gene. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 644-649.
32. Donners, M., Verluyten, M., Bouwman, F., Mariman, E. et al., Proteomic analysis of differential protein expression in human atherosclerotic plaque progression. J. Pathol. 2005, 206, 39-45.
33. Karlsson, H., Mortstedt, H., Lindqvist, H., Tagesson, C., Lindahl, M., Protein profiling of low-density lipoprotein from obese subjects. Proteomics Clin. Appl. 2009, 3, 663-671.
34. Liz, M., Gomes, C., Saraiva, M., Sousa, M., ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J. Lipid Res. 2007, 48, 2385-2395.
35. Kiernan, U., Nedelkov, D., Nelson, R., Multiplexed mass spectrometric immunoassay in biomarker research. A novel approach to the determination of a myocardial infarct. J. Proteome Res. 2006, 5, 2928-2934.
36. Cubedo, J., Padró, T., Alonso, R., Cinca, J. et al., Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis 2012, 222, 263-269.
37. Schaefer, E., Heaton, W., Wetzel, M., Brewer H., Plasma apolipoprotein A-1 absence associated with marked reduction of high density lipoproteins and premature coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 1982, 2, 16-26
38. Wada, M., Iso, T., Asztalos, B., Takama, N. et al., Marked high-density lipoprotein deficiency due to apolipoprotein A-I Tomioka (codon 138 deletion). Atherosclerosis 2009, 207, 157-161
39. Vergeer, M., Holleboom, A., Kastelein, J., Kuivenhooven, J., The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?. J. Lipid Res. 2010, 51, 2058-2073.
40. Sbrana, F., Puntoni, M., Bigazzi, F., Landi, P. et al., High density lipoprotein cholesterol in coronary artery disease: when higher means later. J. Atheroscler. Thromb. 2013, 20, 23-31.
41. Voight, B., Peloso, G., Orho-Melander, M., Frikke-Schmidt, R. et al., Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study. Lancet 2012, 380, 572-580.
42. Rader, D., Tall, A., The not so simple HDL story: is it time to revise the HDL cholesterol hypothesis. Nat. Med. 2013, 18, 1344-1346.